As the current group of pharma ceo's starts to retire or simply work their way into a fine mess (think Fred Hassan), reading the tea leaves to determine the next crop of potential leaders is a favorite sport. And so Pharmaceutical Executive magazine tapped a couple of dozen industry insiders to identify potential up-and-comers who are believed to be the heir apparents, among other things.
Since Andrew Witty, 44, was recently promoted to ceo at Glaxo, no one bothered to nominate him. But there may be some other familiar names. Take a look. Meanwhile, here is an interesting observation - every big drugmaker, but two, is represented on this list by at least one person. Which drugmakers don't have rising stars? Schering-Plough and Lilly.
2 Comments
No one from Schering-Plough, no one from Eli Lilly, and not a single person from any of the major Japanese companies. Even more interesting is the lack of people from CROs. Where are the folks from Quintiles and Covance and the like who are poised to benefit from big pharma's cost-cutting efforts?
Hey-
You guys forgot Rick Asskisser from Eli Lilly and company. This guy would sell his first born to get a promotion.